Electrophysiological Effects of a New Antiarrhythmic Agent, Flecainide, on the Intact Canine Heart

Ab, Hodess; Wp, Follansbee; Jf, Spear; En, Moore

doi:10.1097/00005344-197907000-00005

Cited by 89 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The plasma concentration-response curves in figure 3 indicate that 95% suppression of VEDs -a suppression level not often achieved with other antiarrhythmics22-28 -occurs between approximately 200 and 800 ng/ml. The washout curves shown in figure 4 indicate that 5% return of VEDs occurred between approximately 160 and 800 ng/ml. Thus, the separate estimates of the drug effectiveness-concentration relationship agree remarkably well.…”

Section: Discussionmentioning

confidence: 94%

Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent.

Hodges¹,

Haugland²,

Granrud³

et al. 1982

Circulation

136

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 94%

Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent.

Hodges¹,

Haugland²,

Granrud³

et al. 1982

Circulation

136

View full text Add to dashboard Cite

“…11 Katritsis et al also reported that flecainide prolonged atrial ERP during sinus rhythm, but not during atrial pacing at any heart rate. 12 O'Hara et al 13 and Hodess et al 14 reported that atrial ERP prolongation was more pronounced when flecainide was administered in dogs with pharmacological autonomic nerve block. Although we did not compare the effects in the presence or absence of autonomic nerve block, the sympathetic nerve activity in the present study was expected to be low because of the deep sedation induced by administration of midazolam and fentanyl.…”

Section: Discussionmentioning

confidence: 99%

Frequency-Dependent Electrophysiological Effects of Flecainide, Nifekalant and <i>d,l</i>-Sotalol on the Human Atrium

Watanabe

Nakai

et al. 2001

Jpn Circ J

View full text Add to dashboard Cite

To compare the effects of class Ic and III antiarrhythmic agents on the termination and prevention of atrial fibrillation, the present study investigated the use-dependent electrophysiological effects of flecainide, nifekalant and d,l-sotalol on the human atrium. Flecainide significantly prolonged effective refractory period (ERP), intra-atrial conduction time (IACT) and monophasic action potential duration (MAPD), and its effects on ERP and IACT were use-dependent. Nifekalalant significantly prolonged ERP and MAPD, and these effects were reverse usedependent; however, there was no significant change in IACT. d,l-Sotalol significantly prolonged MAPD and the effect was reverse use-dependent. It significantly prolonged ERP, but the effect was not reverse use-dependent. d,l-Sotalol increased IACT in a use-dependent manner. Thus, for atrial fibrillation, class Ic antiarrhythmic agents might be more effective in termination and class III antiarrhythmic agents might be more effective in prevention. (Jpn Circ J 2001; 65: 1 -6)

show abstract

“…In man, preliminary reports indicate that the drug is effective for treating ventricular arrhythmias (Anderson et al, 1981;Duff et al, 1981;Gulker etal., 1981;Hellestrand etal., 1981a, b;Klempt etal., 1980;Seipel et al, 1981;Somani, 1980). Electrophysiological studies in dogs have shown that flecainide depresses conduction in all myocardial tissues, most notably in the His-Purkinje system and in ventricular muscle (Hodess et al, 1979). In man, flecainide predominantly depresses ventricular conduction (Breithardt & Seipel, 1976;Cowan & Williams, 1981;Olsson & Edvardsson, 1981;Seipel et al, 1980).…”

Section: Introductionmentioning

confidence: 99%

The haemodynamic effect of intravenous flecainide acetate in patients with coronary artery disease.

Serruys¹,

Vanhaleweyk²,

Brand³

et al. 1983

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Flecainide acetate has been shown to be a potent antiarrhythmic agent which is active for more than 8 h, whether given intravenously or orally. However, the negative inotropic effect demonstrated in animal studies could hamper the potential clinical utility of the drug. 2 Ten patients with coronary artery disease but without cardiac failure were given intravenous flecainide (2 mg/kg). Stroke index (SI), left ventricular systolic pressure (LVP), end diastolic pressure (EDP) and LV contractility indices (max dP/dt, VCE 40 mm Hg, peak VCE, Vmax from total pressure (TP)) were measured immediately before and 10 min after flecainide, under resting conditions and during atrial pacing with heart rates up to 133 + 4.2 beats/min (mean + s.e. mean). 3 It is demonstrated that flecainide has a negative inotropic effect, not only under resting conditions, but also less apparently during pacing-induced tachycardia. The effect appears to be dose-related and may result in a reduction of cardiac performance.

show abstract

Electrophysiological Effects of a New Antiarrhythmic Agent, Flecainide, on the Intact Canine Heart

Cited by 89 publications

References 0 publications

Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent.

Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent.

Frequency-Dependent Electrophysiological Effects of Flecainide, Nifekalant and <i>d,l</i>-Sotalol on the Human Atrium

The haemodynamic effect of intravenous flecainide acetate in patients with coronary artery disease.

Contact Info

Product

Resources

About